All News

hospital-834152_640.jpg

Sequential Belimumab and Rituximab in SLE

Jack Cush, MD

Could disease control in active systemic lupus erythematosus (SLE) patients be improved by the sequential use of subcutaneous belimumab (BEL) and intravenous rituximab (RTX)? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.

Read Article
CV,risk,MI,heart,cardiac

Less Mortality with GLP-1 Agonists in Rheumatic Patients

Jack Cush, MD

A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.

Read Article
hands.stiff2_.jpg

More Noninflammatory Pain in Difficult to Treat RA

Jack Cush, MD

A Canadian cohort of difficult-to-treat rheumatoid arthritis (D2T RA) patients shows significantly more non-inflammatory pain in D2T RA compared to patients responding to b/tsDMARDs.

Read Article
cost.healthcare.jpg

The Burden of Rheumatoid Arthritis (2018–2020)

Jack Cush, MD

A recent study that quantified the economic and humanistic burden of rheumatoid arthritis (RA) in the USA showed significantly higher health care expenditures, particularly medication costs, and suboptimal quality of life in RA.

Read Article
lung,cancer,blue,mass

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease

Jack Cush, MD

A matched cohort study from the Veterans Health Administration shows that rheumatoid arthritis patients have a >50% increased risk of lung cancer, and a 3-fold higher risk of lung cancer in RA-interstitial lung disease (ILD).

Read Article
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs The ACR praised the recent announcement from the CMS that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are… https://t.co/GXl6y87ZaF https://t.co/A2N4Ehg8Dk
Dr. John Cush RheumNow ( View Tweet)
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/J9FCdkId8H https://t.co/uJylDP3IIp

Links:

Dr. John Cush RheumNow ( View Tweet)
Less Mortality with GLP-1 Agonists in Rheumatic Patients A recent study in PLOS ONE found that treating type 2 diabetes with GLP-1-RAs lowered the risk of mortality and cardiovascular events in patients with IMIDs and type 2 diabetes. https://t.co/MzCG7WvrDS https://t.co/0RPIfOO0s7

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/GV6WjsqZBH https://t.co/9l9qyJpg3I

Links:

Dr. John Cush RheumNow ( View Tweet)
Among the 1st 10 drug prices Negotiated by Medicare - Two are for Rheums: - Etanercept; original price $7,106/Mo], negotiated price $2,355 (67% decr) - Ustekinumab: for original price $13,836/mo, negotiated price $4,695 (66% decr) https://t.co/eexr4Acrbi https://t.co/fE0aoD8vA3

Links:

Dr. John Cush RheumNow ( View Tweet)
More Noninflammatory Pain in Difficult to Treat RA A Canadian cohort of difficult-to-treat rheumatoid arthritis (D2T RA) patients shows significantly more non-inflammatory pain in D2T RA compared to patients responding to b/tsDMARDs. https://t.co/XRH9q0gNyq

Links:

Dr. John Cush RheumNow ( View Tweet)

The Burden of Rheumatoid Arthritis (2018–2020) A recent study that quantified the economic and humanistic burden of RA in the US showed significantly higher health care expenditures, particularly medication costs, and suboptimal quality of life in RA. https://t.co/1v3CDtZC0l https://t.co/WPWuOvpkfa

Links:

Dr. John Cush RheumNow ( View Tweet)
Mass General Brigham Study 172 RA-ILD pts w/ 6.5 yrs F/U (age 62 yrs): noted (4%) lung transplants & 44 (26%) ILD-related deaths. FVC rapidly declining pts (14%) had aOR 19x lung transplant & aOR 2.8 ILD-related death. Slow decline in 54%, no decline 32% https://t.co/fKDnJIu9a7 https://t.co/ondzN4WZ1F

Links:

Dr. John Cush RheumNow ( View Tweet)
Breast CA (BC) & TNFi - study of 2 cohorts (Optum commercial * SEER/Medicare) found that 17% & 16% of BC pts received TNFi. 1 yr overall survival was no different +/- TNFi (HR= 0.77 & 0.84); but BC survival better on TNFi (HR 0.28; 0.08–0.98) vs csDMARDs. https://t.co/cGqT80rGTR https://t.co/n7i5VNFkVT

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Inflammatory vs non-inflammatory pain in RA - Pain may be more than inflammation - Residual plain is a problem - Consider damage vs FM - Central vs. Neuogenic pain https://t.co/JUgc5IsgMq https://t.co/CRekJsAP04

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3

Links:

Dr. John Cush RheumNow ( View Tweet)
Exploratory study of 22 RA pts w/ mod/severe periodontitis and RA. After periodontal Tx, only pts w/ severe (not moderate) periodontitis had significant reduction in DAS28 and CCP2 levels. Use periodontal Tx in RA management & T2T strategy? https://t.co/X7oXByzTnX https://t.co/b0vwTp4tfd

Links:

Dr. John Cush RheumNow ( View Tweet)
Barriers to Treat-to-Target in Rheumatoid Arthritis A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation. https://t.co/CMEd62BfU0 https://t.co/YHQ408No4S

Links:

Dr. John Cush RheumNow ( View Tweet)
Economic, Personal Burden of RA: Maybe Not So Bad? Data from a major federal survey indicate that people with RA don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found. https://t.co/ZFw7KZ0Wsb https://t.co/bO02YbzWvb

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×